Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12369) 12369
Book Chapter (131) 131
Dissertation (18) 18
Magazine Article (10) 10
Publication (9) 9
Newsletter (5) 5
Conference Proceeding (4) 4
Book / eBook (3) 3
Reference (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (9606) 9606
life sciences & biomedicine (9041) 9041
humans (6479) 6479
animals (6012) 6012
male (5339) 5339
biological and medical sciences (3202) 3202
phosphodiesterase inhibitors - pharmacology (3199) 3199
medical sciences (2501) 2501
rats (2256) 2256
pharmacology & pharmacy (2170) 2170
phosphodiesterase (2033) 2033
female (1967) 1967
mice (1719) 1719
phosphodiesterase inhibitors - therapeutic use (1662) 1662
middle aged (1604) 1604
sildenafil citrate (1539) 1539
erectile dysfunction - drug therapy (1381) 1381
urology & nephrology (1325) 1325
pharmacology. drug treatments (1309) 1309
adult (1278) 1278
biochemistry & molecular biology (1239) 1239
erectile dysfunction (1201) 1201
cyclic amp - metabolism (1187) 1187
sildenafil (1175) 1175
aged (1083) 1083
dose-response relationship, drug (1080) 1080
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (1077) 1077
neurosciences & neurology (1065) 1065
neurosciences (1064) 1064
cell biology (1029) 1029
treatment outcome (981) 981
cells, cultured (971) 971
analysis (949) 949
fundamental and applied biological sciences. psychology (921) 921
phosphodiesterase 5 inhibitors - therapeutic use (877) 877
nitric oxide (869) 869
cyclic nucleotide phosphodiesterases, type 4 (866) 866
impotence (833) 833
tadalafil (828) 828
cyclic gmp - metabolism (823) 823
research (820) 820
signal transduction (811) 811
piperazines - therapeutic use (805) 805
rats, sprague-dawley (803) 803
cardiovascular system & cardiology (766) 766
proteins (765) 765
3',5'-cyclic-amp phosphodiesterases - metabolism (764) 764
in vitro techniques (742) 742
physiology (739) 739
abridged index medicus (738) 738
piperazines - pharmacology (736) 736
phosphoric diester hydrolases - metabolism (724) 724
disease models, animal (718) 718
purines (707) 707
enzymes (683) 683
enzyme inhibitors - pharmacology (681) 681
cyclic nucleotide phosphodiesterases, type 5 (678) 678
phosphodiesterases (676) 676
sulfones (676) 676
research article (651) 651
rats, wistar (631) 631
care and treatment (629) 629
phosphodiesterase inhibitors (621) 621
cardiac & cardiovascular systems (617) 617
time factors (615) 615
drug therapy (611) 611
health aspects (595) 595
rodents (591) 591
respiratory system (580) 580
physiological aspects (569) 569
gene expression (556) 556
cyclic amp (551) 551
rolipram (545) 545
phosphodiesterase inhibitors - administration & dosage (543) 543
phosphorylation (541) 541
science & technology - other topics (538) 538
multidisciplinary sciences (536) 536
kinases (533) 533
camp (527) 527
signal transduction - drug effects (512) 512
medicine & public health (511) 511
mice, inbred c57bl (510) 510
medicine (509) 509
calcium - metabolism (503) 503
chemistry (502) 502
risk factors (499) 499
double-blind method (497) 497
phosphodiesterase 5 inhibitors - pharmacology (496) 496
inflammation (493) 493
phosphodiesterase inhibitors - adverse effects (486) 486
cell line (474) 474
physical sciences (474) 474
sulfones - therapeutic use (471) 471
endocrinology & metabolism (470) 470
apoptosis (468) 468
cyclic nucleotide phosphodiesterases, type 3 (462) 462
phosphodiesterase 5 inhibitors (455) 455
pulmonary hypertension (454) 454
3',5'-cyclic-gmp phosphodiesterases - antagonists & inhibitors (447) 447
sphingomyelin phosphodiesterase - metabolism (437) 437
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12328) 12328
Japanese (124) 124
German (76) 76
Russian (62) 62
French (58) 58
Chinese (37) 37
Portuguese (31) 31
Spanish (21) 21
Korean (7) 7
Polish (5) 5
Italian (4) 4
Norwegian (4) 4
Turkish (4) 4
Dutch (3) 3
Bulgarian (2) 2
Czech (2) 2
Arabic (1) 1
Danish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Serbian (1) 1
Slovak (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Phosphodiesterase inhibitors
by Boswell‐Smith, Victoria and Spina, Domenico and Page, Clive P
British journal of pharmacology, ISSN 0007-1188, 01/2006, Volume 147, Issue S1, pp. S252 - S257
PDE5 | asthma | inflammation | PDE4 | Phosphodiesterase | erectile dysfunction | Erectile dysfunction | Inflammation | Asthma | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Biological and medical sciences | Medical sciences | Chronic obstructive pulmonary disease, asthma | Pharmacology. Drug treatments | Pneumology | Phosphodiesterase Inhibitors - therapeutic use | Erectile Dysfunction - enzymology | Cyclic Nucleotide Phosphodiesterases, Type 4 | Cyclic Nucleotide Phosphodiesterases, Type 5 | Asthma - enzymology | Heart Failure - enzymology | Humans | Cyclic Nucleotide Phosphodiesterases, Type 3 | Phosphodiesterase Inhibitors - pharmacology | Male | Asthma - drug therapy | Heart Failure - drug therapy | Animals | Erectile Dysfunction - drug therapy | Inflammation - drug therapy | 3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors | 3',5'-Cyclic-GMP Phosphodiesterases - antagonists & inhibitors | Inflammation - enzymology | Index Medicus | Applied Pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Phosphodiesterase type 5 (PDE5) inhibitors sensitize topoisomerase II inhibitors in killing prostate cancer through PDE5-independent impairment of HR and NHEJ DNA repair systems
by Chang, Jo-Fan and Hsu, Jui-Ling and Sheng, Yi-Hua and Leu, Wohn-Jenn and Yu, Chia-Chun and Chan, She-Hung and Chan, Mei-Ling and Hsu, Lih-Ching and Liu, Shih-Ping and Guh, Jih-Hwa
Frontiers in oncology, ISSN 2234-943X, 2019, Volume 9, pp. 681 - 681
Phosphodiesterase type 5 inhibitor | Non-homologous end joining DNA repair | Topoisomerase II inhibitor | Homologous recombination DNA repair | PDE5-independent | Life Sciences & Biomedicine | Oncology | Science & Technology | Usage | Care and treatment | Research | Phosphodiesterases | DNA repair | Prostate cancer | phosphodiesterase type 5 inhibitor | homologous recombination DNA repair | non-homologous end joining DNA repair | topoisomerase II inhibitor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension
by Archer, Stephen L and Michelakis, Evangelos D
The New England journal of medicine, ISSN 0028-4793, 11/2009, Volume 361, Issue 19, pp. 1864 - 1871
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases | Medical sciences | Pneumology | Phosphodiesterase Inhibitors - therapeutic use | Sulfones - therapeutic use | Phosphodiesterase Inhibitors - adverse effects | Humans | Middle Aged | Phosphodiesterase 5 Inhibitors | Sulfones - adverse effects | Hypertension, Pulmonary - physiopathology | Anticoagulants - therapeutic use | Dyspnea - etiology | Piperazines - therapeutic use | Piperazines - adverse effects | Warfarin - therapeutic use | Sildenafil Citrate | Diuretics - therapeutic use | Female | Hypertension, Pulmonary - drug therapy | Purines - adverse effects | Purines - therapeutic use | Drug Therapy, Combination | Hypertension, Pulmonary - etiology | Practice Guidelines as Topic | Hypertension | Care and treatment | Usage | Causes of | Diagnosis | Phosphodiesterases | Health aspects | Proteins | Pulmonary arteries | Veins & arteries | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Vision disorders and phosphodiesterase type 5 inhibitors: A review of the evidence to date
by Laties, Alan M
Drug safety, ISSN 0114-5916, 2009, Volume 32, Issue 1, pp. 1 - 18
Pharmacology & Pharmacy | Public, Environmental & Occupational Health | Toxicology | Life Sciences & Biomedicine | Science & Technology | Phosphodiesterase Inhibitors - therapeutic use | Vision Disorders - physiopathology | Phosphodiesterase Inhibitors - adverse effects | Adverse Drug Reaction Reporting Systems | Erectile Dysfunction - drug therapy | Humans | Risk Factors | Phosphodiesterase 5 Inhibitors | Male | Clinical Trials as Topic | Vision Disorders - drug therapy | Index Medicus
Journal Article
Details down arrow
5. Full Text Alpha‐1 adrenergic antagonists, 5‐alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: A systematic review and meta‐analysis of urodynamic studies
by Fusco, Ferdinando and Creta, Massimiliano and De Nunzio, Cosimo and Gacci, Mauro and Li Marzi, Vincenzo and Finazzi Agrò, Enrico
Neurourology and urodynamics, ISSN 0733-2467, 08/2018, Volume 37, Issue 6, pp. 1865 - 1874
5‐alpha reductase inhibitors | alpha‐1adrenergic antagonists | benign prostatic obstruction | benign prostatic enlargement | phosphodiesterase type 5 inhibitors | phytotherapic compounds | alpha-1adrenergic antagonists | 5-alpha reductase inhibitors | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Medicine, Experimental | Sympathomimetic agents | Medical research | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): A randomized controlled trial
by Tapson, Victor F and Torres, Fernando and Kermeen, Fiona and Keogh, Anne M and Allen, Roblee P and Frantz, Robert P and Badesch, David B and Frost, Adaani E and Shapiro, Shelley M and Laliberte, Kevin and Sigman, Jeffrey and Arneson, Carl and Galiè, Nazzareno
Chest, ISSN 0012-3692, 2012, Volume 142, Issue 6, pp. 1383 - 1390
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Cardiology. Vascular system | Biological and medical sciences | Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases | Medical sciences | Pneumology | Sulfones - therapeutic use | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Walking - physiology | Dose-Response Relationship, Drug | Sildenafil Citrate | Young Adult | Epoprostenol - therapeutic use | Epoprostenol - adverse effects | Adult | Female | Hypertension, Pulmonary - drug therapy | Phosphodiesterase 5 Inhibitors - therapeutic use | Purines - therapeutic use | Drug Therapy, Combination | Endothelin Receptor Antagonists | Double-Blind Method | Administration, Oral | Familial Primary Pulmonary Hypertension | Treatment Outcome | Piperazines - therapeutic use | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Epoprostenol - analogs & derivatives | Sulfonamides - therapeutic use | Exercise Tolerance - physiology | Adolescent | Aged | Epoprostenol - administration & dosage | Treprostinil | Dosage and administration | Research | Drug therapy | Patient outcomes | Pulmonary hypertension | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 Study): A randomized controlled trial
by Tapson, Victor F and Jing, Zhi-Cheng and Xu, Kai-Feng and Pan, Lei and Feldman, Jeremy and Kiely, David G and Kotlyar, Eugene and McSwain, C. Shane and Laliberte, Kevin and Arneson, Carl and Rubin, Lewis J and FREEDOM-C2 Study Team
Chest, ISSN 0012-3692, 2013, Volume 144, Issue 3, pp. 952 - 958
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Exercise Tolerance - drug effects | Dose-Response Relationship, Drug | Young Adult | Time Factors | Adult | Female | Blood Pressure - drug effects | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Endothelin Receptor Antagonists | Double-Blind Method | Administration, Oral | Phosphodiesterase 5 Inhibitors - administration & dosage | Familial Primary Pulmonary Hypertension | Treatment Outcome | Epoprostenol - analogs & derivatives | Adolescent | Aged | Vasodilator Agents - administration & dosage | Epoprostenol - administration & dosage | Complications and side effects | Care and treatment | Patient outcomes | Treprostinil | Clinical trials | Dosage and administration | Research | Drug therapy | Pulmonary hypertension | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phosphodiesterase type 5 inhibitors for erectile dysfunction
by Carson, Culley C and Lue, Tom F
BJU international, ISSN 1464-4096, 08/2005, Volume 96, Issue 3, pp. 257 - 280
tadalafil | phosphodiesterase type 5 | safety | pharmacokinetics | cGMP | vardenafil | sildenafil | efficacy | erectile dysfunction | Tadalafil | Phosphodiesterase type 5 | Efficacy | Erectile dysfunction | Vardenafil | Safety | Sildenafil | Pharmacokinetics | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Nephrology. Urinary tract diseases | Biological and medical sciences | Genital system. Reproduction | Medical sciences | Pharmacology. Drug treatments | Phosphodiesterase Inhibitors - therapeutic use | Phosphodiesterase Inhibitors - adverse effects | Phosphodiesterase Inhibitors - pharmacokinetics | Cyclic Nucleotide Phosphodiesterases, Type 5 | Humans | Erectile Dysfunction - diagnosis | Male | Treatment Outcome | Erectile Dysfunction - etiology | Forecasting | Phosphoric Diester Hydrolases | Algorithms | Drug Interactions | Erectile Dysfunction - drug therapy | Penile Erection - drug effects | 3',5'-Cyclic-GMP Phosphodiesterases | Penile Erection - physiology | Prostatic Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma
by Loeb, Stacy and Folkvaljon, Yasin and Lambe, Mats and Robinson, David and Garmo, Hans and Ingvar, Christian and Stattin, Pär
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 06/2015, Volume 313, Issue 24, pp. 2449 - 2455
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Phosphodiesterase 5 Inhibitors - adverse effects | Carcinoma, Basal Cell - chemically induced | Humans | Middle Aged | Risk Factors | Logistic Models | Male | Skin Neoplasms - chemically induced | Case-Control Studies | Socioeconomic Factors | Drug Prescriptions - statistics & numerical data | Sweden | Animals | Erectile Dysfunction - drug therapy | Melanoma - chemically induced | Aged, 80 and over | Registries | Aged | Phosphodiesterase 5 Inhibitors - therapeutic use | Inhibitor drugs | Risk assessment | Clinical outcomes | Melanoma
Journal Article
Details down arrow